Skip to main content
Erschienen in: Medical Oncology 11/2016

01.11.2016 | Original Paper

High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection

verfasst von: Zhenhai Lu, Jianhong Peng, Zhiqiang Wang, Zhizhong Pan, Yunfei Yuan, Desen Wan, Binkui Li

Erschienen in: Medical Oncology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Oligometastasis is defined as a transitional state between localized and widespread systemic metastatic cancers. In colorectal cancer, the prognostic factors and prognostic value of preoperative serum carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) for patients with colorectal liver oligometastases (CLOM) undergoing hepatic resection have not been well explored. Therefore, the present study included 141 patients with CLOM (≤5 liver metastases) who underwent R0 resection from 2005 to 2012. The association of clinicopathological factors including preoperative CA19-9 and CEA levels with overall survival (OS) was analyzed with univariate and multivariate analyses. Kaplan–Meier analysis showed that patients with high CA19-9 levels tended to have poorer OS than those with low levels (median OS 21.5 vs. 64.0 months, P = 0.002). Preoperative CEA levels were not significantly associated with OS (P > 0.05). Univariate and multivariate analyses demonstrated that larger tumor size of liver metastases (HR 1.911; 95 % CI 1.172–3.114; P = 0.009), bilobar distribution (HR 1.776; 95 % CI 1.097–2.873; P = 0.019), and higher preoperative CA19-9 levels (HR 1.954; 95 % CI 1.177–3.242; P = 0.010) were independent predictors of poor OS for patients with CLOM. Our study identified tumor size, distribution, and preoperative CA19-9 levels as independent prognostic factors for OS of patients with CLOM. In particular, measurement of preoperative CA19-9 levels offers an easy tool that could help identify high-risk patients and aid in improving the management of patients with CLOM.
Literatur
7.
Zurück zum Zitat Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77(7):1254–62.CrossRefPubMed Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77(7):1254–62.CrossRefPubMed
8.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18 (discussion 18–21).CrossRefPubMedPubMedCentral Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18 (discussion 18–21).CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231(4):487–99.CrossRefPubMedPubMedCentral Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000;231(4):487–99.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Chapman MA, Buckley D, Henson DB, Armitage NC. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer. 1998;78(10):1346–9.CrossRefPubMedPubMedCentral Chapman MA, Buckley D, Henson DB, Armitage NC. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer. 1998;78(10):1346–9.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Gobbi PG, Valentino F, Berardi E, Tronconi C, Brugnatelli S, Luinetti O, et al. New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. Br J Cancer. 2008;98(2):328–34. doi:10.1038/sj.bjc.6604114.CrossRefPubMed Gobbi PG, Valentino F, Berardi E, Tronconi C, Brugnatelli S, Luinetti O, et al. New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. Br J Cancer. 2008;98(2):328–34. doi:10.​1038/​sj.​bjc.​6604114.CrossRefPubMed
15.
Zurück zum Zitat Lech G, Slotwinski R, Krasnodebski IW. The role of tumor markers and biomarkers in colorectal cancer. Neoplasma. 2014;61(1):1–8.CrossRefPubMed Lech G, Slotwinski R, Krasnodebski IW. The role of tumor markers and biomarkers in colorectal cancer. Neoplasma. 2014;61(1):1–8.CrossRefPubMed
16.
Zurück zum Zitat Levy M, Visokai V, Lipska L, Topolcan O. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma. 2008;55(2):138–42.PubMed Levy M, Visokai V, Lipska L, Topolcan O. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma. 2008;55(2):138–42.PubMed
17.
Zurück zum Zitat Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.PubMed Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.PubMed
20.
Zurück zum Zitat Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. doi:10.1093/annonc/mdw235.CrossRefPubMed Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. doi:10.​1093/​annonc/​mdw235.CrossRefPubMed
21.
23.
Zurück zum Zitat Petrelli F, Coinu A, Zaniboni A, Pietrantonio F, Barni S. Prognostic factors after R0 resection of colorectal cancer liver metastases: a systematic review and pooled-analysis. Rev Recent Clin Trials. 2016;11(1):56–62.CrossRefPubMed Petrelli F, Coinu A, Zaniboni A, Pietrantonio F, Barni S. Prognostic factors after R0 resection of colorectal cancer liver metastases: a systematic review and pooled-analysis. Rev Recent Clin Trials. 2016;11(1):56–62.CrossRefPubMed
24.
25.
Zurück zum Zitat Filella X, Molina R, Grau JJ, Pique JM, Garcia-Valdecasas JC, Astudillo E, et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg. 1992;216(1):55–9.CrossRefPubMedPubMedCentral Filella X, Molina R, Grau JJ, Pique JM, Garcia-Valdecasas JC, Astudillo E, et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg. 1992;216(1):55–9.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Nakayama T, Watanabe M, Teramoto T, Kitajima M. CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol. 1997;66(4):238–43.CrossRefPubMed Nakayama T, Watanabe M, Teramoto T, Kitajima M. CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol. 1997;66(4):238–43.CrossRefPubMed
28.
Zurück zum Zitat Lin PC, Lin JK, Lin CC, Wang HS, Yang SH, Jiang JK, et al. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. Int J Colorectal Dis. 2012;27(10):1333–8. doi:10.1007/s00384-012-1447-1.CrossRefPubMed Lin PC, Lin JK, Lin CC, Wang HS, Yang SH, Jiang JK, et al. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. Int J Colorectal Dis. 2012;27(10):1333–8. doi:10.​1007/​s00384-012-1447-1.CrossRefPubMed
29.
Zurück zum Zitat Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum. 2004;47(2):227–32.CrossRefPubMed Morita S, Nomura T, Fukushima Y, Morimoto T, Hiraoka N, Shibata N. Does serum CA19-9 play a practical role in the management of patients with colorectal cancer? Dis Colon Rectum. 2004;47(2):227–32.CrossRefPubMed
30.
32.
Zurück zum Zitat Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15(12):3433–9. doi:10.1245/s10434-008-0168-8.CrossRefPubMed Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15(12):3433–9. doi:10.​1245/​s10434-008-0168-8.CrossRefPubMed
33.
Zurück zum Zitat Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57.PubMedPubMedCentral Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57.PubMedPubMedCentral
34.
Zurück zum Zitat Wang RF, Song BR, Peng JJ, Cai GX, Liu FQ, Wang MH, et al. The prognostic value of preoperative serum CEA and CA19-9 values in stage I–III colorectal cancer. Hepatogastroenterology. 2014;61(132):994–9.PubMed Wang RF, Song BR, Peng JJ, Cai GX, Liu FQ, Wang MH, et al. The prognostic value of preoperative serum CEA and CA19-9 values in stage I–III colorectal cancer. Hepatogastroenterology. 2014;61(132):994–9.PubMed
Metadaten
Titel
High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection
verfasst von
Zhenhai Lu
Jianhong Peng
Zhiqiang Wang
Zhizhong Pan
Yunfei Yuan
Desen Wan
Binkui Li
Publikationsdatum
01.11.2016
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 11/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0838-5

Weitere Artikel der Ausgabe 11/2016

Medical Oncology 11/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.